|
151 |
The effects of spilanthol (SA3X) supplementation on muscle size and strength in healthy men – a randomized parallel-group placebo-controlled trial
Enthalten in Journal of complementary and integrative medicine Bd. 22, 2025, Nr. 4: 713-724. 12 S.
|
|
|
|
152 |
Effects of evening primrose oil on treating painful diabetic neuropathy: a randomized, double-blind, clinical trial
Enthalten in Journal of complementary and integrative medicine Bd. 22, 2025, Nr. 3: 547-554. 08 S.
|
|
|
|
153 |
Exploring the impact of herbaceous Apiaceae family plants on primary dysmenorrhea: a systematic review protocol
Enthalten in Journal of complementary and integrative medicine Bd. 22, 2025, Nr. 2: 373-377. 05 S.
|
|
|
|
154 |
The impact of Omega-3 supplementation on arrhythmia reduction in acute coronary syndrome patients: a randomized clinical trial
Enthalten in Journal of complementary and integrative medicine Bd. 22, 2025, Nr. 1: 173-180. 08 S.
|
|
|
|
155 |
The Missing Window of Opportunity and Quasi-Experimental Effects of Institutional Integration: Evidence from Ukraine
Enthalten in Review of law and economics Bd. 21, 2025, Nr. 2: 561-576. 16 S.
|
|
|
|
156 |
Effect of vibration on pain during subcutaneous heparin injection: A randomized, single-blind, placebo-controlled trial
Enthalten in Open medicine Bd. 20, 2025, Nr. 1. 10 S.
|
|
|
|
157 |
Can Urban “Gold Signboards” Yield Carbon Reduction Dividends? A Quasi-Natural Experiment Based on the “National Civilized City” Selection
Enthalten in Economics / Journal articles Bd. 19, 2025, Nr. 1. 13 S.
|
|
|
|
158 |
Osimertinib verbessert bei EGFR-mutiertem NSCLC auch das Gesamtüberleben
Enthalten in Onkologische Welt Bd. 16, 2025, Nr. 08: 448-449
|
|
|
|
159 |
NSCLC Stadium 3: Osimertinib verlängert progressionsfreies Überleben
Enthalten in Onkologische Welt Bd. 16, 2025, Nr. 07: 372-372
|
|
|
|
160 |
NSCLC: Perioperative PD-1-Inhibition ein echter Schritt nach vorn
Enthalten in Onkologische Welt Bd. 16, 2025, Nr. 05: 232-232
|
|
Administration
